Clinical Trials Logo

Clinical Trial Summary

This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery. Ilorasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02540876
Study type Interventional
Source University of Chicago
Contact
Status Completed
Phase Phase 1
Start date September 8, 2015
Completion date February 8, 2019

See also
  Status Clinical Trial Phase
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Active, not recruiting NCT03834961 - Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Phase 2
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01017640 - Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Phase 1
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT03775616 - Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers N/A
Active, not recruiting NCT03098277 - Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy N/A
Completed NCT00503854 - Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Terminated NCT02414724 - Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma Phase 1
Active, not recruiting NCT02876068 - Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies Phase 1
Active, not recruiting NCT02142803 - TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Phase 1
Completed NCT00085553 - Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Recruiting NCT03023202 - UWCCC Molecular Tumor Board Registry
Active, not recruiting NCT02706366 - Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors Phase 1
Active, not recruiting NCT01552356 - Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors Phase 1
Withdrawn NCT02567396 - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Completed NCT02360215 - Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases Phase 3
Withdrawn NCT03804255 - Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Completed NCT02646319 - Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Early Phase 1